Torre L, Bray F, Siegel R, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87-108.
Sittka A, Schmeck B. MicroRNAs in the lung In microRNA cancer regulationSpringer. Heidelberg 2013; pp. 121-34.
Rudin CM, Durinck S, Stawiski EW, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 2012; 44: 1111-6.
Travis WD, Brambilla E, Burke AP, et al. Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart. J Thorac Oncol 2015; 10: 1240-2.
George J, Lim JS, Jang SJ, et al. Comprehensive genomic profiles of small cell lung cancer. Nature 2015; 524: 47.
Lind H, Zienolddiny S, Ryberg D, et al. Interleukin 1 receptor antagonist gene polymorphism and risk of lung cancer: a possible interaction with polymorphisms in the interleukin 1 beta gene. Lung Cancer 2005; 50: 285-90.
Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers-a different disease. Nat Rev Cancer 2007; 7: 778.
Amos C, Xu W, Spitz M. Is there a genetic basis for lung cancer susceptibility? In chemoprevention of cancer. Springer Chicago 1999; pp. 3-12.
Bach PB, Kelley MJ, Tate RC, et al. Screening for lung cancer: a review of the current literature. Chest 2003; 123: S72-82.
Heuvelmans MA, Groen HJ, Oudkerk M. Early lung cancer detection by low-dose CT screening: therapeutic implications. Expert Rev Respir Med 2017; 11: 89-100.
Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75: 843-54.
Pasquinelli AE, Reinhart BJ, Slack F, et al. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 2000; 408: 86.
Johnson CD, Esquela-Kerscher A, Stefani G, et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 2007; 67: 7713-22.
Wang L, Zhang L-F, Wu J, et al. IL-1β-mediated repression of microRNA-101 is crucial for inflammation-promoted lung tumorigenesis. Cancer Res 2014; 74(17): 4720-30.
Gasparini P, Cascione L, Landi L, et al. microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers. Proc Natl Acad Sci USA 2015; 112: 14924-9.
Hu L, Ai J, Long H, et al. Integrative microRNA and gene profiling data analysis reveals novel biomarkers and mechanisms for lung cancer. Oncotarget 2016; 7: 8441.
Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513-8.
Qu WQ, Liu L, Yu Z. Clinical value of microRNA-23a upregulation in non-small cell lung cancer. Int Clin Exp Med 2015; 8: 13598-603.
Capodanno A, Boldrini L, Proietti A, et al. Let-7g and miR-21 expression in non-small cell lung cancer: correlation with clinicopathological and molecular features. Int J Oncol 2013; 43: 765-74.
Gao Y, Dai M, Liu H, et al. Diagnostic value of circulating miR-21: an update meta-analysis in various cancers and validation in endometrial cancer. Oncotarget 2016; 7: 68894-908.
Jazbutyte V, Thum T. MicroRNA-21: from cancer to cardiovascular disease. Curr Drug Targets 2010; 11: 926-35.
Meng F, Henson R, Wehbe–Janek H, et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007; 133: 647-58.
Frankel LB, Christoffersen NR, Jacobsen A, et al. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem 2008; 283(2): 1026-33.
Asangani IA, Rasheed SA, Nikolova D, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor PDCD4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008; 27: 2128.
Liu S, Sun X, Wang M, et al. A microRNA 221- and 222-mediated feedback loop maintains constitutive activation of NFkappaB and STAT3 in colorectal cancer cells. Gastroenterology 2014; 147: 847-59.
Ma G, Dai W, Sang A, et al. Upregulation of microRNA-23a/b promotes tumor progression and confers poor prognosis in patients with gastric cancer. Int Clin Exp Pathol 2014; 7: 8833.
Zhang X-W, Liu N, Chen S, et al. High microRNA-23a expression in laryngeal squamous cell carcinoma is associated with poor patient prognosis. Diagn Pathol 2015; 10: 22.
Cao M, Seike M, Soeno C, et al. MiR-23a regulates TGF-β-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells. Int Oncol 2012; 41: 869-75.
Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship Mayo Clin proc Mayo Clinic 2008; 83: 584-94.
Hamam R, Ali AM, Alsaleh KA, et al. microRNA expression profiling on individual breast cancer patients identifies novel panel of circulating microRNA for early detection. Sci Rep 2016; 6: 25997.
Petricoin EF 3rd, Ornstein DK, Paweletz CP, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002; 94: 1576-8.
MacFarlane LA. R Murphy P. MicroRNA: biogenesis, function and role in cancer. Curr Genomics 2010; 11: 537-61.
Zhou X, Yang P-C. MicroRNA: a small molecule with a big biological impact. MicroRNA 2012; 1(1): 1.
Shen J, Liu Z, Todd NW, et al. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer 2011; 11: 374.
Shen J, Todd NW, Zhang H, et al. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest 2011; 91: 579.
Markou A, Sourvinou I, Vorkas P, et al. Clinical evaluation of microRNA expression profiling in non small cell lung cancer. Lung Cancer 2013; 81: 388-96.
Tang D, Shen Y, Wang M, et al. Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer. Eur J Cancer Prev 2013; 22: 540-8.
Markou A, Zavridou M, Lianidou ES. miRNA-21 as a novel therapeutic target in lung cancer. Lung Cancer: Targets Ther 2016; 7: 19.
Novello S, Barlesi F, Califano R, et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27: v1-v27.
Vucic EA, Thu KL, Pikor LA, et al. Smoking status impacts microRNA mediated prognosis and lung adenocarcinoma biology. BMC Cancer 2014; 14: 778.
Izzotti A, Longobardi M, La Maestra S, et al. Release of microRNAs into body fluids from ten organs of mice exposed to cigarette smoke. Theranostics 2018; 8: 2147.
Suzuki K, Yamada H, Nagura A, et al. Association of cigarette smoking with serum microRNA expression among middle-aged Japanese adults. Fujian Med J 2016; 2: 1-5.
Qu W-Q, Liu L, Yu Z. Clinical value of microRNA-23a upregulation in non-small cell lung cancer. Int Clin Exp Med 2015; 8: 13598.
Liu X-G, Zhu W-Y, Huang Y-Y, et al. High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med Oncol 2012; 29: 618-26.
Wei J, Gao W, Zhu C-J, et al. Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin J Cancer 2011; 30: 407.